U10 Ful Member Application Affiliated with SWOG

描述（由申请人提供）：UT m.d. Anderson癌症中心（MDACC）于2002年11月作为正式成员加入西南肿瘤小组（SWOG）。这是我们的第一个U10会员申请。在成为SWOG正式会员之前的三年中，MDACC平均每年进行51项SWOG治疗研究。我们的SWOG项目将整合MDACC综合多学科资源的许多要素，包括16个专业护理中心，在那里，大多数MDACC患者作为门诊患者在多学科，多模式的团队方法中接受治疗。MDACC拥有895名癌症研究人员，其中包括536名临床人员。2001年，MDACC治疗了62,600名癌症患者，其中16,144人是新诊断的，3,500人参加了治疗方案。协调SWOG研究的结构包括首席研究员，联合首席研究员，CRA主任，SWOG项目指导委员会和每个疾病现场项目的负责人（医学肿瘤学家，放射治疗师，外科医生）。每一位MDACC-SWOG项目的疾病现场负责人都是MDACC部门的主席，他在癌症医学部门的执行委员会中担任主席，由Dr. wwan Ki Hong领导，他热情地支持MDACC的SWOG治疗/累积活动。在过去的6年里，MDACC对SWOG的重大行政贡献包括：癌症控制研究委员会主席和SWOG执行委员会/科学顾问委员会成员（Lippman博士）；胃肠委员会主席

DESCRIPTION (provided by applicant): The UT M. D. Anderson Cancer Center (MDACC) joined the Southwest Oncology Group (SWOG) as a full member in November 2002. This is our first U10 member application. During the past 3 years and entirely prior to becoming a full SWOG member, MDACC averaged 51 accruals to SWOG therapy studies per year. Our SWOG Program will integrate many elements of MDACCs comprehensive multidisciplinary resources, including 16 specialized Care Centers, where most MDACC patients are treated as outpatients in a multidisciplinary, multimodality team approach. MDACC has 895 cancer research faculty, including 536 clinical faculty. In 2001, MDACC cared for 62,600 cancer patients, of whom 16,144 were newly diagnosed and 3,500 were enrolled in therapeutic protocols. The structure for coordinating SWOG studies includes the Principal Investigator, Co-Principal Investigator, Head CRA, SWOG Program Steering Committee, and leaders of each disease-site program (medical oncologists, radiotherapists, surgeons). Every MDACC-SWOG Program disease-site leader is a MDACC department chair sitting on the Executive Council of the Division of Cancer Medicine headed by Dr. Waun Ki Hong, who enthusiastically supports SWOG therapy/accrual activities within MDACC. Substantial MDACC administrative contributions to SWOG in the past 6 years include Chair, Cancer Control Research Committee and member, SWOG Executive Committee/Scientific Advisory Board (Dr. Lippman); Chair, Gastrointestinal Committee (Dr. Abbruzzese); Co-Chair, Brain Committee (Dr. Sawaya); Vice Chair, Lung Developmental Therapeutics Committee (Dr. Herbst); Chair, Testis Subcommittee (Dr. Logothetis); and Vice Chair, Sarcoma (Special Populations) Committee (Dr. Bleyer). At least 21 MDACC faculty are official members of SWOG and contribute actively to several SWOG committees on a regular basis (e.g., the Gastrointestinal, Brain, Lung, H & N, and Sarcoma committees). Dr. EI-Naggar will head the SWOG H&N Tumor Biology and Correlative Science Subcommittee. Dr. P. Pisters is a consultant for the SWOG Sarcoma Specimen Board. At least 11 MDACC faculty provided scientific leadership as Study Coordinators in 17 SWOG-coordinated protocols (including 3 in development) and co-authored 18 SWOG papers (since 2000). MDACC will apply its historical strengths in developing innovative Phase I, II studies within the SWOG setting. Phase III trials are highly complex and difficult for any single institution to conduct alone, and MDACC looks forward to leading some and joining other SWOG efforts to test novel approaches in Phase Ill, standard-of-care-altering trials.